Information Provided By:
Fly News Breaks for January 27, 2016
PCRX
Jan 27, 2016 | 07:30 EDT
After surveying 26 oral/maxillofacial surgeons to gauge the use Exparel now that oral surgeries like wisdom tooth extractions are covered in the label, Piper Jaffray analyst David Amsellem reiterates an Overweight rating on Pacira Pharmaceuticals with a $93 price target. Pacira's Exparel is poised to see significant adoption in wisdom tooth extractions, the analyst tells investors in a research note, citing his survey.
News For PCRX From the Last 2 Days
There are no results for your query PCRX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.